A randomized phase II study of intermittent chemotherapy or intermittent chemotherapy with maintenance GM-CSF [sargramostim] in patients with previously untreated hormone-refractory prostate cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Sargramostim (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 Jan 2015 Status changed from active, no longer recruiting to completed.
- 09 Apr 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.